Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tarsa Completes Phase III For Oral Calcitonin In Osteoporosis, Plans 2011 NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Initially, biotech will pursue a treatment indication but also has its recombinant oral formulation in Phase II for osteoporosis prevention.
Advertisement

Related Content

Financings Of The Fortnight Sees The Blooming Of New Life Sciences Funding Sources In The EU
Tarsa Raises $28 Million Series B to Support Regulatory Filings of Oral Calcitonin
Warner Chilcott’s Launch Of Atelvia Hits Headwinds
Warner Chilcott’s Launch Of Atelvia Hits Headwinds

Topics

Advertisement
UsernamePublicRestriction

Register

PS072516

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel